Search...
/
The Fly Cast
Press play to listen
Smarter market moves start here
Competitive Advantages
Pioneering Market Leadership: Glaukos effectively created and continues to dominate the Micro-Invasive Glaucoma Surgery (MIGS) market, establishing significant first-mover advantages in physician adoption and market education.
Expansive Product Portfolio: Beyond their foundational MIGS devices, Glaukos is diversifying into sustained pharmaceutical delivery systems for glaucoma and other ophthalmic conditions, broadening their revenue streams and market reach.
Robust Clinical Validation: Their key products, like the iStent family, are supported by extensive and compelling clinical data demonstrating long-term safety and efficacy, building physician confidence and trust.
Risks
Intense Competition and Market Share Erosion: Glaukos operates in a highly competitive ophthalmology market with established players and emerging technologies vying for market share in glaucoma treatment.
Regulatory Hurdles and Compliance Risks: Obtaining and maintaining necessary approvals from regulatory bodies like the FDA and international agencies for medical devices is complex, time-consuming, and subject to strict compliance requirements.
Reimbursement Policy Changes and Coverage Limits: The company's commercial success is significantly dependent on favorable reimbursement policies and adequate coverage from government healthcare programs and private insurers for its devices and procedures.
Today
7:02 AM
Over a week ago
Jun 17, 7:30 AM
Jun 11, 6:26 AM
May 26, 2:50 PM
May 21, 7:42 AM
Apr 30, 8:31 AM
Apr 30, 8:27 AM
Apr 30, 8:10 AM
Apr 30, 7:24 AM
Apr 30, 7:16 AM
Apr 30, 6:35 AM
Apr 29, 4:27 PM
Apr 29, 4:26 PM
Apr 15, 4:06 PM
Apr 7, 6:46 AM
Mar 24, 3:56 PM
Mar 19, 7:05 AM
Mar 12, 4:08 PM
Feb 18, 7:18 AM